Since IDH mutation are associated with poor patient survival in glioblastoma, we separately assessed the prognostic significance of MAGEH1 in patients harboring these IDH genotypes, Interestingly, reduced MAGEH1 expression exhibited a strong association with poor OS in glioma patients harboring either wild type (HR=2.37, 95% CI=1.42–3.94, p<0.001, Figure 7C) or mutant (HR= 1.94, 95% CI=1.2–3.16, p<0.01, Figure 7D) genotypes. This evidence concerns the gene MAGEH1 and glioma.